Seeking Alpha

AstraZeneca (AZN) intends to axe 2,300 sales and administration positions as part of its...

AstraZeneca (AZN) intends to axe 2,300 sales and administration positions as part of its overhaul, adding to 1,600 R&D job cuts already announced. AstraZeneca, which is due to lay out its strategy at an investor meeting today, plans to continue paying dividends and to buy in new technology The company is paying up to $420M plus royalties for the rights to the technology of Moderna, a developer of drugs using messenger RNA, which is involved in protein production in cells. (PR I, II)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs